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Background: Pancreatic cancer has a poor prognosis. Because the response to existing therapies is limited, 
gene therapy may offer a new approach to treatment. Efficient adenovirus infection of target cells depends upon the 
presence of the Coxackie and adenovirus surface receptor CAR. 
Aim: To evaluate the potential efficacy of adenoviral therapy in pancreatic cancer, we evaluated expression 
of CAR in human pancreatic cancer cell lines and archival tissues of pancreatic cancer and normal pancreas. 
Method: Surface CAR expression in 10 human pancreatic cancer cell lines was analysed by flow cytometry 
following treatment with a polyclonal rabbit anti-CAR antibody. CAR expression was correlated with the efficiency of 
transduction of these cell lines with recombinant Ad5CMVEGFP virus. Using the same antibody, immunostaining was 
performed on tissue microarrays containing 188 pancreatic ductal adenocarcinomas and 68 matched controls. 
Results: The level of surface CAR expression varied amongst the pancreatic cancer cell lines, and correlated 
with their susceptibility to adenoviral transduction. Immunostaining for CAR was absent in 103 (55%) of 
adenocarcinomas, while moderate and strong staining was observed in 59 (31%) and 26 (14%) cases, respectively. 
Absence of CAR immunolabeling correlated with poor histological differentiation and clear cell morphology of 
pancreatic cancer. In normal tissue, strong immunolabeling was seen in the majority of islet cells as well as in 
peripheral and interlobular pancreatic ducts. 
Conclusion: Absence of CAR expression in a considerable proportion of pancreatic cancers and constitutive CAR 
expression in normal pancreatic tissue may reduce the suitability of adenoviral gene therapy in pancreatic cancer 
patients. 
 
